US 7,514,594 B2
	Transgenic animal model of bone mass modulation
G. Roger Askew, Boxford, Mass. (US); Philip Babij, Dunstable, Mass. (US); Frederick James Bex, III, Newton Square, Pa. (US); and Peter Van Nest Bodine, Havertown, Pa. (US)
Assigned to Wyeth, Madison, N.J. (US)
Filed on Oct. 08, 2003, as Appl. No. 10/680,287.
Prior Publication US 2004/0244069 A1, Dec. 02, 2004
Int. Cl. A01K 67/00 (2006.01); A01K 67/033 (2006.01); A01K 67/027 (2006.01); C12N 5/00 (2006.01); C12N 5/02 (2006.01); C12N 5/06 (2006.01); C12N 5/10 (2006.01)

U.S. Cl. 800—18  [800/8; 800/9; 800/13; 800/14; 435/325; 435/354]

15 Claims

1. A transgenic mouse having somatic and germ cells comprising a stably integrated nucleic acid which comprises a murine or viral promoter region that directs protein expression in transgenic mouse bone cells that is operably linked to a sequence encoding a human HBM protein or a sequence encoding a mouse LRP5 protein having a glycine 170 to valine substitution, and wherein said transgenic mouse has increased bone density.